Evidence map›Paper›PMID 15378304›Full record

ReviewJournal of neurology2004

Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Jürg Kesselring

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neurology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Life issues in multiple sclerosis.Nature reviews. Neurology · 2010
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jürg KesselringDepartment of Rehabilitation, Rehabilitation Centre Klinik Valens, 7317, Valens, Switzerland. kesselring.klival@spin.ch

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and handicap. The symptoms, which contribute to loss of independence and restrictions in the participation in social activities, are often responsible for a continuing decline in quality of life. The main objective of rehabilitation is, therefore, to ease the burden of symptoms by improving self-performance and independence. Compensation of functional deficits, adaptation and reconditioning, together with management of symptoms, impairment, emotional coping and self-estimation, are all important long-term objectives. Although rehabilitation has no direct influence on disease progression, recent studies indicate that this form of intervention improves personal activities and participation in social activities, thereby improving quality of life. The improvements often outlast the treatment period by several months. These findings suggest that quality of life is determined by disability and handicap more than by functional deficit and disease progression.

Indexed as

Evidence-Based MedicineHumansMultiple Sclerosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.